Abstract:

Objective To observe the effects and adverse reactions of bevacizumab in brain metastases patients with serious cerebral edema. Methods

Retrospective analysis of 14 cases of brain metastasis patients with serious cerebral edema， including 7 cases of breast cancer， 5 cases of lung cancer， 1

case of esophagus cancer and 1 case of adenoid cystic carcinoma. Mannitol， dexamethasone and other conventional treatment were not effective in these patients. The symptom， quality of life and the volume of edema in T2 weighted MRI images before and after the bevacizumab treatment were compared. The adverse reactions were recorded in detail. Results The medium dose of bevacizumab was 4.76 mg/kg. The symptoms of 11 cases of brain metastases were significantly relieved after the bevacizumab treatment. Brain MRI indicated that the edema volumes before and after the treatment were reduced significantly［（38 804±14 859）mm3 vs.（80 100±28 338）mm3，P=0.02］. The edema index had a reduced trend（15.38±7.12 vs. 26.40±16.52，P＞0.05）. Adverse reactions associated with bevacizumab included bleeding in the nasal cavity and death in 1 patient， and hypertension in 3 patient. There were no proteinuria， anemia， stomatitis and other complications. Conclusion Bevacizumab has significant efficacy for treating serious cerebral edema， but patients should be selected carefully before receiving bevacizumab to avoid serious adverse reactions.